Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study

Gemcitabine and 5-fluorouracil are the only two compounds with reproducible activity against advanced pancreatic cancer (APC). We have evaluated a novel combination of gemcitabine and 5-fluorouracil on the clinical benefit response (CBR) end point. Eleven consecutive patients with symptomatic APC we...

Descripción completa

Detalles Bibliográficos
Autores principales: Matano, E, Tagliaferri, P, Libroia, A, Damiano, V, Fabbrocini, A, De Lorenzo, S, Bianco, A R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363227/
https://www.ncbi.nlm.nih.gov/pubmed/10839289
http://dx.doi.org/10.1054/bjoc.1999.1139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363227/
https://www.ncbi.nlm.nih.gov/pubmed/10839289
http://dx.doi.org/10.1054/bjoc.1999.1139

Ejemplares similares